Brief: Entrada Therapeutics Reports Third Quarter 2023 Financial Results
07/11/2023 12:09
Nov 7 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL
RESULTS
* ENTRADA THERAPEUTICS- CASH RUNWAY EXPECTED THROUGH 2025
WITH
$354 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
AS OF SEPTEMBER 30, 2023
Source text for Eikon: ID:nGNX9G5JLc
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview